Predicted protein targets (top 7)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | NPC1 | O15118 | 2/20 | 0.48 |
| ▸ | RAB9A | P51151 | 2/20 | 0.48 |
| ▸ | CXCR2 | P25025 | 18/20 | 0.47 |
| ▸ | CCR7 | P32248 | 3/20 | 0.46 |
| ▸ | CXCR1 | P25024 | 1/20 | 0.45 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.43 |
| ▸ | CX3CR1 | P49238 | 1/20 | 0.42 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL490245 | 0.90 | CXCR2 (0.50) | CXCR2CCR7 | |
| SCHEMBL3853163 | 0.90 | RAB9A (0.57) | NPC1RAB9ACXCR2CCR7CXCR1 | |
| SCHEMBL6354578 | 0.89 | MGAM (0.51) | NPC1RAB9ACXCR2SMN1; SMN2CX3CR1 | |
| SCHEMBL6639107 | 0.85 | RAB9A (0.51) | NPC1RAB9ASMN1; SMN2 | |
| SCHEMBL490008 | 0.84 | NPC1 (0.48) | NPC1RAB9ACXCR2CCR7CXCR1 | |
| SCHEMBL5951413 | 0.84 | RAB9A (0.51) | NPC1RAB9ACXCR2CCR7CXCR1 | |
| SCHEMBL3754582 | 0.81 | CXCR2 (0.45) | NPC1RAB9ACXCR2CCR7CXCR1 | |
| SCHEMBL6637576 | 0.80 | NPC1 (0.48) | NPC1RAB9ASMN1; SMN2 | |
| SCHEMBL6635771 | 0.79 | CYP3A4 (0.56) | NPC1RAB9ACXCR2SMN1; SMN2CX3CR1 | |
| SCHEMBL1487154 | 0.79 | CXCR2 (0.45) | CXCR2CCR7CXCR1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 24 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7790883-B2 | Process for the preparation of thiazolopyrimidines | ASTRAZENECA AB (SE) | 2010-09-07 | — | — | US | disclosed |
| US-7790883-B2 | Process for the preparation of thiazolopyrimidines | ASTRAZENECA AB (SE) | 2010-09-07 | — | — | US | disclosed |
| US-7790883-B2 | Process for the preparation of thiazolopyrimidines | ASTRAZENECA AB (SE) | 2010-09-07 | — | — | US | disclosed |
| US-20100217000-A1 | Process for the Preparation of Thiazolopyrimidines | ASTRAZENECA AB (SE) | 2010-08-26 | — | — | US | disclosed |
| US-20100217000-A1 | Process for the Preparation of Thiazolopyrimidines | ASTRAZENECA AB (SE) | 2010-08-26 | — | — | US | disclosed |
| US-20100217000-A1 | Process for the Preparation of Thiazolopyrimidines | ASTRAZENECA AB (SE) | 2010-08-26 | — | — | US | disclosed |
| EP-1711505-B1 | PROCESS FOR THE PREPARATION OF THIAZOLOPYRIMIDINES | ASTRAZENECA AB (SE) | 2010-06-23 | — | — | EP | disclosed |
| EP-1711505-B1 | PROCESS FOR THE PREPARATION OF THIAZOLOPYRIMIDINES | ASTRAZENECA AB (SE) | 2010-06-23 | — | — | EP | disclosed |
| US-20090239882-A1 | Thiazolopyramidine Compounds for the Modulation of Chemokine Receptor Activity | ASTRAZENECA AB (SE) | 2009-09-24 | — | — | US | disclosed |
| US-20090043097-A1 | Methods | ASTRAZENECA AB (SE) | 2009-02-12 | — | — | US | disclosed |
| US-20070282103-A1 | Process for the Preparation of Thiazolopyrimidines | ASTRAZENECA AB (SE) | 2007-12-06 | — | — | US | disclosed |
| EP-1844054-A2 | THIAZOLOPYRIMIDINE COMPOUNDS FOR THE MODULATION OF CHEMOKINE RECEPTOR ACTIVITY | AstraZeneca AB (SE) | 2007-10-17 | — | — | EP | disclosed |
| EP-1419158-B1 | PTERIDINONE DERIVATIVES AS MODULATORS OF CHEMOKINE RECEPTOR ACTIVITY | ASTRAZENECA AB (SE) | 2007-08-01 | — | — | EP | disclosed |
| US-20070142352-A1 | Pteridinone Derivatives as Modulators of Chemokine Receptor Activity | ASTRAZENECA AB (SE) | 2007-06-21 | — | — | US | disclosed |
| EP-1711505-A2 | PROCESS FOR THE PREPARATION OF THIAZOLOPYRIMIDINES | AstraZeneca AB (SE) | 2006-10-18 | — | — | EP | disclosed |
| WO-2006064228-A2 | THIAZOLOPYRAMIDINE COMPOUNDS FOR THE MODULATION OF CHEMOKINE RECEPTOR ACTIVITY | ASTRAZENECA AB (SE) | 2006-06-22 | — | — | WO | disclosed |
| WO-2005056563-A2 | PROCESS FOR THE PREPARATION OF THIAZOLOPYRIMIDINES | ASTRAZENECA AB (SE) | 2005-06-23 | — | — | WO | disclosed |
| US-20050010047-A1 | Pteridinone derivatives as modulators of chemokine receptor activity | BONNERT ROGER VICTOR (GB) | 2005-01-13 | — | — | US | disclosed |
| EP-1419158-A1 | PTERIDINONE DERIVATIVES AS MODULATORS OF CHEMOKINE RECEPTOR ACTIVITY | Astrazeneca AB (SE) | 2004-05-19 | — | — | EP | disclosed |
| WO-2003024966-A1 | PTERIDINONE DERIVATIVES AS MODULATORS OF CHEMOKINE RECEPTOR ACTIVITY | ASTRAZENECA AB (SE) | 2003-03-27 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (6 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090043097-A1 | Methods | CYP21A2, CYP17A1, HSD17B7 | NPC1 77/4885RAB9A 2396/4885CXCR2 2692/4885 |
| US-20050010047-A1 | Pteridinone derivatives as modulators of chemokine receptor activity | CCR5, CXCR3, CCR2 | NPC1 1970/4885RAB9A 1135/4885CXCR2 11/4885 |
| US-20070282103-A1 | Process for the Preparation of Thiazolopyrimidines | TPMT, TYMP, DPYD | NPC1 1858/4885RAB9A 3258/4885CXCR2 2764/4885 |
| US-20100217000-A1 | Process for the Preparation of Thiazolopyrimidines | TPMT, TYMP, DPYD | NPC1 1354/4885RAB9A 3144/4885CXCR2 2645/4885 |
| US-20070142352-A1 | Pteridinone Derivatives as Modulators of Chemokine Receptor Activity | CCR5, CXCR3, CCR2 | NPC1 1970/4885RAB9A 1135/4885CXCR2 11/4885 |
| US-20090239882-A1 | Thiazolopyramidine Compounds for the Modulation of Chemokine Receptor Activity | ACKR3, CXCR1, CCL11 | NPC1 550/4885RAB9A 1777/4885CXCR2 5/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.